Evidence map›Paper›PMID 40996646›Full record

ArticleBulletin of experimental biology and medicine2025

Production of Recombinant Nucleocapsid Protein SARSN1 and Its Use for Assessing the Immune Response in Mice after Vaccination with a Live Probiotic Vaccine Containing the Coronavirus Nucleocapsid Protein.

T V Gupalova, E A Bormotova, G F Leontieva, T A Kramskaya, Yu A Desheva, A N Suvorov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

T V GupalovaInstitute of Experimental Medicine, St. Petersburg, Russia. tvgupalova@rambler.ru.
E A BormotovaInstitute of Experimental Medicine, St. Petersburg, Russia.
G F LeontievaInstitute of Experimental Medicine, St. Petersburg, Russia.
T A KramskayaInstitute of Experimental Medicine, St. Petersburg, Russia.
Yu A DeshevaInstitute of Experimental Medicine, St. Petersburg, Russia.
A N SuvorovInstitute of Experimental Medicine, St. Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nucleocapsid (N) protein of the severe acute respiratory syndrome coronavirus (SARSCoV) is the most abundant structural protein in virus-infected cells. Its primary function is to pack ~30 kb positive-sense viral RNA genome that includes a 5' cap into a ribonucleoprotein (RNP) complex known as capsid. Among the 4 major structural proteins of SARS-CoV, the N protein exhibits the highest expression levels in the host cells. We produced a recombinant SARS-CoV N protein (SARSN1) and used it to detect specific antibodies in mice vaccinated with a live probiotic vaccine containing the coronavirus nucleocapsid protein.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19 VaccinesNucleocapsid ProteinsProbioticsSevere acute respiratory syndrome-related coronavirusViral VaccinesAnimalsAntibodies, ViralFemaleMiceMice, Inbred BALB CRecombinant ProteinsVaccinationAntibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19 VaccinesNucleocapsid ProteinsRecombinant ProteinsViral Vaccineslive probiotic vaccinerecombinant nucleocapsid (N) proteinSARS-CoV coronavirus

Identifiers

PMID40996646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.